avanbulin

Avanbulin (BAL27862) is a novel synthetic small molecule that acts as a potent microtubule-destabilizing agent by binding to the colchicine site on tubulin. It inhibits tubulin polymerization, disrupts the microtubule network essential for cell division, and induces apoptosis in cancer cells. Avanbulin demonstrates activity against tumor models resistant to standard microtubule-targeting agents such as taxanes and vinca alkaloids. The drug has been shown to overcome resistance mediated by P-glycoprotein overexpression and various tubulin modifications. Its unique mechanism of action results in distinct effects on microtubule organization compared to other agents in its class[1][2][4][6][9]. Avanbulin is the active moiety of lisavanbulin (BAL101553), an orally available prodrug developed for clinical use[3][5][7].

Other names

avanbulinBAL27862BAL-27862BAL 27862